Also, we recommend selective suppression of pathogenic M2a proteins e.g. TGM2, CCL17/CCL22, TGF-β1, and murine Arg1, FIZZ1 and CHI3L3, for the future developments of effective therapies for allergic asthma. This evidence concerns the gene CCL22 and allergic asthma.